본문 바로가기
KERD
논문KCI 등재

Genotype-phenotype correlations and long-term efficacy of pamidronate therapy in patients with osteogenesis imperfecta

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

주제분류소아과학

초록

Purpose: Osteogenesis imperfecta (OI) is a rare bone fragility disorder caused by defects in type 1 collagen biosynthesis. This study investigated the genotype-phenotype correlations and the efficacy of pamidronate therapy in patients with OI in a single academic center. Methods: This study included 24 patients with OI. A clinical scoring system was used to evaluate disorder severity. COL1A1 and COL1A2 genes were analyzed in 13 patients using Sanger sequencing. Genotype-phenotype correlations and the efficacy of pamidronate therapy were analyzed through a retrospective medical chart review. Results: Of the 24 patients, 18 (75%) were classified as type I (12 with type Ia and 6 with type Ib), 2 as type III (8.4%), and 4 as type IV (16.7%). Type Ia patients showed relatively higher lumbar bone mineral density (BMD) standard deviation scores (SDS) and lower clinical scores than those with other types. Seven patients with qualitative mutations had lower lumbar BMD-SDS (P=0.015) and higher clinical scores (P=0.008) than 6 patients with quantitative mutations. The annual fracture frequency and lumbar BMD-SDS improved in patients with qualitative mutations after pamidronate treatment. Conclusion: This study demonstrated that OI patients with qualitative mutations in COL1A1/2 had a more severe phenotype than those with quantitative mutations. Patients with qualitative mutations showed a significant reduction in fracture frequency and an increase in lumbar BMD-SDS after pamidronate treatment. Clinical score and genotype might be helpful for predicting phenotype and response to pamidronate therapy in OI patients.

Abstract

Purpose: Osteogenesis imperfecta (OI) is a rare bone fragility disorder caused by defects in type 1 collagen biosynthesis. This study investigated the genotype-phenotype correlations and the efficacy of pamidronate therapy in patients with OI in a single academic center. Methods: This study included 24 patients with OI. A clinical scoring system was used to evaluate disorder severity. COL1A1 and COL1A2 genes were analyzed in 13 patients using Sanger sequencing. Genotype-phenotype correlations and the efficacy of pamidronate therapy were analyzed through a retrospective medical chart review. Results: Of the 24 patients, 18 (75%) were classified as type I (12 with type Ia and 6 with type Ib), 2 as type III (8.4%), and 4 as type IV (16.7%). Type Ia patients showed relatively higher lumbar bone mineral density (BMD) standard deviation scores (SDS) and lower clinical scores than those with other types. Seven patients with qualitative mutations had lower lumbar BMD-SDS (P=0.015) and higher clinical scores (P=0.008) than 6 patients with quantitative mutations. The annual fracture frequency and lumbar BMD-SDS improved in patients with qualitative mutations after pamidronate treatment. Conclusion: This study demonstrated that OI patients with qualitative mutations in COL1A1/2 had a more severe phenotype than those with quantitative mutations. Patients with qualitative mutations showed a significant reduction in fracture frequency and an increase in lumbar BMD-SDS after pamidronate treatment. Clinical score and genotype might be helpful for predicting phenotype and response to pamidronate therapy in OI patients.

참고문헌 (39)

  1. Forlino A, "New perspectives on osteogenesis imperfecta", Nat Rev Endocrinol, 7, pp.540~557 (2011)
  2. Forlino A, "Osteogenesis imperfecta", Lancet, 387, pp.1657~1671 (2016)
  3. Sillence DO, "Classification of osteogenesis imperfect", Lancet, 1, pp.1041~1042 (1978)
  4. Chetty M, "The evolution of the nosology of osteogenesis imperfecta", Clin Genet, 99, pp.42~52 (2021)
  5. Van Dijk FS, "Classification of osteogenesis imperfecta revisited", Eur J Med Genet, 53, pp.1~5 (2010)
  6. Aglan MS, "A scoring system for the assessment of clinical severity in osteogenesis imperfecta", J Child Orthop, 6, pp.29~35 (2012)
  7. Schleit J, "Molecular outcome, prediction, and clinical consequences of splice variants in COL1A1, which encodes the proα1(I)chains of type I procollagen", Hum Mutat, 36, pp.728~739 (2015)
  8. Tournis S, "Osteogenesis imperfecta-a clinical update", Metabolism, 80, pp.27~37 (2018)
  9. Rauch F, "Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta", J Bone Miner Res, 25, pp.1367~1374 (2010)
  10. Morello R, "CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta", Cell, 127, pp.291~304 (2006)
  11. Christiansen HE, "Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta", Am J Hum Genet, 86, pp.389~398 (2010)
  12. Martinez-Glez V, "Identification of a mutation causing deficient BMP1", MTLD proteolytic activity in autosomal recessive osteogenesis imperfecta, 2012, pp.33, 343~350
  13. Puig-Hervas MT, "Mutations in PLOD2 cause autosomal-recessive connective tissue disorders within the Bruck syndrome-osteogenesis imper fect a phenot ypi c spect rum", Hum Mutat, 33, pp.1444~1449 (2012)
  14. Kelley BP, "Mutations in FKBP10 cause recessive osteogenesis imperfecta and bruck syndrome", J Bone Miner Res, 26, pp.666~672 (2011)
  15. Laine CM, "WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta", N Engl J Med, 368, pp.1809~1816 (2013)
  16. Cho SY, "Osteogenesis imperfecta type I caused by a novel mutation in the start codon of the COL1A1 gene in a Korean family", Ann Clin Lab Sci, 45, pp.100~105 (2015)
  17. 최진호, "Short-term Efficacy of Monthly Pamidronate Infusion in Patients with Osteogenesis Imperfecta", Journal of Korean Medical Science, 22(2), pp.209~212 (2007), 대한의학회
  18. 김재현, "The 2017 Korean National Growth Charts for children and adolescents: development, improvement, and prospects", Clinical and Experimental Pediatrics, 61(5), pp.135~149 (2018), 대한소아청소년과학회
  19. Kang MJ, "Body composition and bone density reference data for Korean children, adolescents, and young adults according to age and sex : Results of the 2009-2010 Korean national health and nutrition examination survey(KNHANES)", J Bone Miner Metab, 34, pp.429~439 (2016)
  20. Lee SH, "Bone mineral density of proximal femur and spine in Korean children between 2 and 18 years of age", J Bone Miner Metab, 25, pp.423~430 (2007)
  21. Astrom E, "Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta", Arch Dis Child, 86, pp.356~364 (2002)
  22. Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology", Genet Med, 17, pp.405~424 (2015)
  23. Liu Y, "Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese osteogenesis imperfecta patients revealed by targeted next generation sequencing", Osteoporos Int, 28, pp.2985~2995 (2017)
  24. Peng H, "A novel splicing mutation in COL1A1 gene caused type I osteogenesis imperfecta in a Chinese family", Gene, 502, pp.168~171 (2012)
  25. Zhytnik L, "COL1A1", 2 pathogenic variants and phenotype characteristics in Ukrainian osteogenesis imperfecta patients, 2019, pp.10, 722~
  26. Maioli M, "Genotype-phenotype correlation study in 364 osteogenesis imperfecta Italian patients", Eur J Hum Genet, 27, pp.1090~1100 (2019)
  27. Mrosk J, "Diagnostic strategies and genotype-phenotype correlation in a large Indian cohort of osteogenesis imperfecta", Bone, 110, pp.368~377 (2018)
  28. Lindahl K, "Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta", Eur J Hum Genet, 23, pp.1042~1050 (2015)
  29. Andersson K, "Mutations in COL1A1and COL1A2 and dental aberrations in children and adolescents with osteogenesis imperfecta-a retrospective cohort study", PLoS One, 12, pp.e0176466~ (2017)
  30. Lund AM, "Dental mani festat ions of osteogenesis imperfecta and abnormalities of collagen I metabolism", J Craniofac Genet Dev Biol, 18, pp.30~37 (1998)
  31. Rauch F, "Genotypephenotype correlations in nonlethal osteogenesis imperfecta caused by mutations in the helical domain of collagen type I", Eur J Hum Genet, 18, pp.642~647 (2010)
  32. Thuesen KJ, "The dental perspective on osteogenesis imperfecta in a Danish adult population", BMC Oral Health, 18, pp.175~ (2018)
  33. Morello R, "Osteogenesis imperfecta and therapeutics", Matrix Biol, 71-72, pp.294~312 (2018)
  34. Sato A, "Scoliosis in osteogenesis imperfecta caused by COL1A1", COL1A2mutations-genotype-phenotype correlations and effect of bisphosphonate treatment, 2016, pp.86, 53~57
  35. Dwan K, "Bisphosphonate therapy for osteogenesis imperfecta", Cochrane Database Syst Rev, 10, pp.CD005088~ (2016)
  36. Lindahl K, "Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with pamidronate", Bone, 87, pp.11~18 (2016)
  37. 조태준, "골형성 부전증 소아 환자에 대한 주기적 파미드로네이트 정주 요법의 치료 효과", 대한정형외과학회지, 38(7), pp.15~747 (2003), 대한정형외과학회
  38. 정윤석, "골형성부전증 환자에서 파미드로네이트의 치료 효과", Endocrinology and Metabolism, 19(5), pp.485~491 (2004), 대한내분비학회
  39. Yi KH, "Reference values for bone mineral density according to age with body size adjustment in Korean children and adolescents", J Bone Miner Metab, 32, pp.281~289 (2014)

관련 논문AI추천

Successful Pamidronate Treatment of Osteogenesis Imperfecta Type III Infant with Multiple Fractures백종욱, 심은정, 윤주희, 황일태대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2012 · 제17권 제3호Denosumab use in osteogenesis imperfecta: an update on therapeutic approachesFerjani Hanene Lassoued, Hamdi Wafa, Kaffel Dhia, Maatallah Kaouther, Majdoub Fatma, Nessib Dorra Ben대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2023 · 제28권 제2호Zoledronate Therapy in Osteogenesis Imperfecta: Perspectives in Indonesia Tertiary HospitalAliefio Japamadisaw, Dian Nurhayati, Rob G. H. H. Nelissen, Tri Wahyu Martanto대한골대사학회 · 대한골대사학회지2024 · 제31권 제4호Efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescentsChoi Jin-Ho, Choi Yunha, Lee Yena, Yoo Han-Wook, Yoon Ji-Hee대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2021 · 제26권 제2호Osteogenesis imperfecta and combined orthodontics and orthognathic surgery: a case report on two siblingsDong-Young Kim, Ju-Hong Jeon, Unbong Baik대한구강악안면외과학회 · 대한구강악안면외과학회지2020 · 제46권 제1호Effectiveness and safety of pamidronate treatment in nonambulatory children with low bone mineral densityChae Hyun Wook, Choi Han Saem, Kim Ho-Seong, Kwon Ahreum, Lee Hae In, Lee Myeongseob, Song Kyungchul, Suh Junghwan대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2024 · 제29권 제1호

이 간행물의 다른 논문 (11건)